- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00968981
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
June 8, 2017 updated by: Genentech, Inc.
A Phase Ib, Open-Label, Dose-Scheduling Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a two stage, Phase Ib study designed to describe the pharmacokinetics of GDC-0449 in patients with advanced solid tumors that are refractory to treatment or for whom no standard therapy exists.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
67
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Histologically documented, incurable, locally advanced or metastatic solid malignancy that has progressed after first-line and second-line therapy (if there is a second-line therapy that has been shown to provide clinical benefit); patients with basal cell carcinoma will be excluded from this study unless they do not qualify for another open GDC-0449 clinical trial
- For patients with disease that is evaluable by physical examination only, diagnosis must also include biomarker confirmation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Documented negative pregnancy test for women of childbearing potential and agreement to use an effective form of contraception for the duration of the study
- Adequate hematopoietic capacity
- Adequate hepatic function
- Adequate renal function
- At least 3 weeks since last chemotherapy, investigational agent, radiation therapy, or major surgical procedure and recovery to pre-treatment baseline or stabilization of all treatment-related toxicities
Exclusion Criteria
- Known, untreated central nervous system (CNS) malignancies or treated brain metastases that are not radiographically stable for ≥ 3 months
- Active infection requiring intravenous (IV) antibiotics
- Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with hepatitis
- Any medical condition or diagnosis that would likely impair absorption of an orally administered drug (e.g., gastrectomy, ileal bypass, chronic diarrhea, gastroparesis)
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications
- Pregnant or lactating
- Treatment with excluded medications, including strong CYP450 inhibitors and inducers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
|
Daily oral repeating dose
Three times weekly oral repeating dose
Once weekly oral repeating dose
|
Experimental: B
|
Daily oral repeating dose
Three times weekly oral repeating dose
Once weekly oral repeating dose
|
Experimental: C
|
Daily oral repeating dose
Three times weekly oral repeating dose
Once weekly oral repeating dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady-State for Both Total and Unbound GDC-0449
Time Frame: Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
|
Number of Participants With Greater Than (>) 50 Percent (%) Decrease in Trough Concentration at Steady State (Css, Trough)
Time Frame: Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
Percent change = ([trough concentration on Day 15 minus trough concentration on Day 57] divided by trough concentration on Day 15) multiplied by 100.
|
Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
Ratio of Total and Unbound Trough GDC-0449 Concentration Between Day 57 to Day 15
Time Frame: Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
Ratio = trough concentration on Day 57 divided by trough concentration on Day 15.
If the ratio of total and unbound trough GDC-0449 concentration between Day 57 to Day 15 is less than 1, then it indicates reduction in total and unbound trough GDC-0449 concentration between Day 15 to Day 57.
|
Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
Plasma Concentration at Steady State (Css) for Total and Unbound GDC-0449
Time Frame: Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
Plasma GDC-0449 concentrations were reported in nanogram per milliliter (ng/mL) units and converted to micromolar (mcM) units using the molecular weight (421.30
grams per mole [g/mol]) prior to PK analysis.
Css was calculated for Days 28 to 56.
|
Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
Maximum Plasma Concentration (Cmax) of Total and Unbound GDC-0449
Time Frame: 0, 1, 2, 4, 6, 24, 48, 72 hours on Day 1, 15 and 57 post-dose
|
Plasma GDC-0449 concentrations were reported in ng/mL units and converted to mcM units using the molecular weight (421.30
g/mol) prior to PK analysis.
|
0, 1, 2, 4, 6, 24, 48, 72 hours on Day 1, 15 and 57 post-dose
|
Area Under the Curve From Time Zero to 24 Hour (AUC0-24) for Total and Unbound GDC-0449
Time Frame: Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
AUC is a measure of the serum concentration of the drug over time.
It is used to characterize drug absorption.
AUC values were calculated using the linear trapezoidal method when the concentrations were rising and using the logarithmic trapezoidal method when the concentrations were declining (linear up/log down rule in WinNonlin).
Below the limit of quantitation (BLQ) values at pre-dose were considered as zero for PK analysis.
|
Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) for Total and Unbound GDC-0449
Time Frame: Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
AUC values were calculated using the linear trapezoidal method when the concentrations were rising and using the logarithmic trapezoidal method when the concentrations were declining (linear up/log down rule in WinNonlin).
BLQ values at pre-dose were considered as zero for PK analysis.
|
Predose and 1, 2, 4, 6, 24, 48, and 72 on Days 1, 29, 50, and 54 and predose on Days 8, 10, 15, 22, 33, 36, 43, and 57
|
Time to Achieve Maximum Observed Plasma Concentration (Tmax) After a Single Dose of GDC-0449
Time Frame: 0, 1, 2, 4, 6, 24, 48, 72 hours on Day 1
|
0, 1, 2, 4, 6, 24, 48, 72 hours on Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Disease Progression or Death
Time Frame: Screening, Day 57, and every 8 weeks thereafter up to 52 weeks
|
Disease progression (assessed by Response Evaluation Criteria in Solid Tumors [RECIST]) was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions or the appearance of one or more new lesions and/or unequivocal progression of existing non target lesions.
|
Screening, Day 57, and every 8 weeks thereafter up to 52 weeks
|
Percentage of Participants With a Response by Best Overall Response (BOR)
Time Frame: Screening Day 57, and every 8 weeks thereafter up to 52 weeks
|
BOR was defined as the best overall response observed during the treatment period according to RECIST.
CR: disappearance of all TLs, with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 mm.
PR: at least a 30% decrease in the sum of diameters of TLs, taking as reference the BL sum diameters.
Progressive disease (PD): at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the baseline sum if that is the smallest on study).
In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm.
Stable disease (SD) was defined as neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
|
Screening Day 57, and every 8 weeks thereafter up to 52 weeks
|
Progression-Free Survival (PFS) Time
Time Frame: Screening Day 57, and every 8 weeks thereafter up to 52 weeks
|
PFS defined as the time from study treatment initiation to the first occurrence of disease progression, as determined by the investigator review of tumor assessments using RECIST, or death from any cause during the study (i.e., within 30 days after the last dose of study treatment).
|
Screening Day 57, and every 8 weeks thereafter up to 52 weeks
|
Duration of Response (DR)
Time Frame: Screening Day 57, and every 8 weeks thereafter up to 52 weeks
|
DR during first line therapy is defined as the time from when response (complete response [CR] or partial response [PR]) was first documented to first documented disease progression or death (whichever occurs first) during first line therapy.
This was only be calculated for participants who achieved a best overall response of CR or PR.
Participants who did not progress or die after they had a confirmed response were censored at the date of their last tumor measurement or last follow up for progression of disease during first line therapy.
CR: disappearance of all target lesions (TLs) with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 millimeters.
PR: at least a 30% decrease in the sum of diameters of TLs, with reference to baseline sum diameters.
DR was not calculated as only 1 responding participant reached their response at the last scheduled response assessment, hence follow-up data are not available.
|
Screening Day 57, and every 8 weeks thereafter up to 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jennifer Low, M.D., Genentech, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2009
Primary Completion (Actual)
October 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
August 28, 2009
First Submitted That Met QC Criteria
August 28, 2009
First Posted (Estimate)
August 31, 2009
Study Record Updates
Last Update Posted (Actual)
July 11, 2017
Last Update Submitted That Met QC Criteria
June 8, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- SHH4610g
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Cancers
-
Agenus Inc.CompletedAdvanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1United States
-
Hoffmann-La RocheCompletedSolid CancersUnited States, Belgium, France, Spain
-
Hoffmann-La RocheCompleted
-
Medical University of South CarolinaCompletedSolid CancersUnited States
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
Clinical Trials on GDC-0449
-
National Cancer Institute (NCI)CompletedAdult MedulloblastomaUnited States
-
Stanford UniversityNational Cancer Institute (NCI); University Hospitals Cleveland Medical CenterCompletedRecurrent Skin Cancer | Basal Cell Carcinoma of the SkinUnited States
-
National Cancer Institute (NCI)Completed
-
Genentech, Inc.Completed
-
National Cancer Institute (NCI)Genentech, Inc.TerminatedChronic Graft Versus Host DiseaseUnited States
-
Genentech, Inc.CompletedA Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell CarcinomaBasal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
Genentech, Inc.Approved for marketingBasal Cell CarcinomaUnited States
-
Lisa BaxRoche Pharma AG; Genentech, Inc.TerminatedPancreatic Ductal AdenocarcinomaUnited Kingdom
-
National Cancer Institute (NCI)Active, not recruitingMesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Clear Cell Chondrosarcoma | Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Primary Central ChondrosarcomaFrance